Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Dissacharide

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20090221525FUNCTIONAL FOODS AGAINST TUMORS - The present invention relates to the technical field of functional foods, more precisely novel functional foods for the treatment and/or prevention of malignant carcinomas of the human or animal body, and also to processes for producing such functional foods.09-03-2009
20100056469Pesticidal Active Mixtures Comprising Aminothiazoline Compounds - Pesticidal mixtures comprising aminothiazoline compounds The present invention relates to pesticidal mixtures comprising as active compounds 1) at least one aminothiazoline compound I of the Formula (I) wherein R03-04-2010
20130085117Compositions Comprising Plant Material and Sugar For The Control of Pests and Methods of Making - Compositions and methods for controlling pests are described. The compositions comprise (a) a material obtainable from a plant comprising an effective amount of a glucosinolate breakdown product and (b) a sugar. The novel compositions exhibit improved properties over known formulations, for example with respect to their potency, ease of manufacture and ease of application.04-04-2013
20100113382COMBINED USE OF DIPEPTIDYL PEPTIDASE 4 INHIBITOR AND SWEETENER - The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity.05-06-2010
20130079298NEW LOW MOLECULAR WEIGHT COMPLEXES BETWEEN IRON AND MALTOBIONIC ACID, USE THEREOF FOR INTRAMUSCULAR OR SUBCUTANEOUS ADMINISTRATION IN THE TREATMENT OF ANEMIC STATES, AND NEW PHARMACEUTICAL COMPOSITIONS ADAPTED FOR THESE USES - New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.03-28-2013
20090306011Use Of An Alkyl Glycoside Or Of A Mixture Of At Least Two Alkyl Glycosides As Agent Intended For Inhibiting Microbial Growth, And Compositions Containing It - The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition.12-10-2009
20090118226INTESTINAL EOSINOPHIL-SUPPRESSING COMPOSITION - To promote the growth of human beings or animals, prevent the onset of diarrhea and prevent or ameliorate various diseases, it is intended to provide a substance which has an effect of decreasing eosinophils in the intestinal tract and a feed comprising the same as a feed additive. Namely, an intestinal eosinophil-suppressing composition which contains an ▪-linked galactooligosaccharide as the active ingredient. When added in an amount of from 0.01 to 10% by weight, in terms of the saccharide, to an animal feed, this composition is useful in providing an intestinal eosinophil-suppressing feed.05-07-2009
20110028424OIL-IN-WATER MICROEMULSION CARRYING LARGE AMOUNT OF OIL - An oil-in-water microemulsion is provided, which includes, on the basis of its total weight, the following components of A) 55-95 wt % of a water phase; B) 0.1-20 wt % of an oil phase, wherein the oil phase comprises at least one oil/fat component containing polyoxypropylene chains; and C) 1-25 wt % of an oil-in-water nonionic emulsifier, wherein the emulsifier is selected from the following group of: hydrophilic nonionic surfactants with polyoxyethylene chains as hydrophilic groups, polyglycerol fatty acid esters, polyglycerol fatty alcohol ethers, sucrose fatty acid esters, and hydrocarbyl polyglycosides. The oil-in-water microemulsion carries a large amount of oil. In addition, the use of an oil/fat containing polyoxypropylene chains is disclosed for increasing the amount of oil carried in an oil-in-water microemulsion.02-03-2011
20110281816FUNGICIDALLY ACTIVE COMPOUND COMBINATIONS - The invention relates to novel fungicidally active compound combinations of 2′-cyano-3,4-dichloroisothiazole-5-carboxanilide of the formula11-17-2011
20110301116NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF - [Problems] The object of the present invention is to provide a Medical Drugs which reduce damage of gastrointestinal mucosal induced by NSAIDs.12-08-2011
20100035837THERAPEUTIC OR PROPHYLACTIC AGENT FOR VASOCONSTRICTION - An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction.02-11-2010
20090281055PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY - The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose, or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient. The method comprises administering palatinose, or a derivative thereof, in combination with the compound.11-12-2009
20120190641Use of Non-Digestible Oligosaccharides - Use of a non-digestible oligosaccharide or salt thereof for producing an anti proliferative effect in a subject wherein the non-digestible oligosaccharide is of formulae (i) [A]-[B]07-26-2012
20120190642ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis.07-26-2012
20110201569Methods For Treating Myocardial Disorders - Provided are methods for treating myocardial disorders comprising administering to a subject an effective amount of a compound of formula (I)08-18-2011
20120295865SHARK-LIKE CHONDROITIN SULPHATE AND PROCESS FOR THE PREPARATION THEREOF - The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and its in vitro biological and anti-inflammatory effectiveness has been shown to be comparable to that of natural products making this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.11-22-2012
20120295866Synthesis And Use Of Glycoside Pro-Drug Analogs - The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs. This invention relates to a method for the production of a broad group of glycosylated drugs, including but not limited to propofol, acetaminophen, and camptothecin carbohydrate derivatives.11-22-2012
20100029581NUTRITIONAL SUPPLEMENT - A nutritional supplement comprises about 2 parts roasted, ground flaxseed, about 2 parts of chick pea flour, about 1.5-2 parts of whole wheat or brown rice flour, about 1 part of raw, ground almonds and optionally, about 0.5-1 part of whole wheat bran. The supplement may additionally contain one or both of raw blue agave nectar and sunflower oil. The supplement may also contain cardamom and/or ginger. The nutritional supplement comprises at least about 1.5 grams of Omega-3 fatty acids, less than about 1.5 grams (g) of glucose, and less than about 0.6 g of sucrose in a serving of about 2 ounces (about 59 ml). A method of supplementing the nutrition of an individual comprises administering the nutritional supplement to the individual.02-04-2010
20100249058FEED ADDITIVE AND FEED - To provide safe and easy means for preventing or treating diseases of birds and mammals, in particular, livestock. In particular, to provide means for preventing or treating an infectious disease caused by a Gram-positive bacterium. In addition, to improve fermentation in the rumen of a ruminant animal, to contribute to suppression of the generation of greenhouse gas, and to increase the feed efficiency. Mannosylerythritol lipids (MEL) and/or rhamnolipids are given to birds or mammals.09-30-2010
20100249057TREHALOSE COMPOUND AND PHARMACEUTICAL COMPRISING THE COMPOUND - The object of the present invention is to provide a novel trehalose compound having a high affinity for an adenosine A3 receptor. The trehalose compound of the present invention is represented by General Formula (1):09-30-2010
20080207558Process for the Preparation of Trivalent Iron Complexes with Mono-, Di- and Polysaccharide Sugars - Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0.08-28-2008
20080274998Disaccharide Molecules and Derivatives Thereof and Methods of Using Same - The present invention is of a method and compounds for mediating a biological activity mediated by moesin, and in particular, for such a method and compounds for mediating a biological activity that is capable of being mediated through binding of a disaccharide to moesin.11-06-2008
20100130442Lung Injury Treatment - Techniques for lung injury treatment are provided. For example, a technique for treating a lung injury in a patient includes the step of administering a therapeutically effective amount of a sophorolipid to the patient.05-27-2010
20080207559Carbohydrates mixture - A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed,08-28-2008
20080269163Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis - Described herein are methods for protecting cells from ultrasound-mediated cytolysis.10-30-2008
20110207694MAMMALIAN HYPOTHALAMIC NUTRIENT MODULATION OF GLUCOSE METABOLISM - Provided are methods of reducing glucose production in a mammal, methods of reducing food intake in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, methods of reducing peripheral blood glucose levels in a mammal, methods of decreasing serum triglyceride levels in a mammal, and methods of decreasing very low density lipoprotein (VLDL) levels in a mammal.08-25-2011
20100152130TREATMENT OF CANCER WITH GLUTAMINE - Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.06-17-2010
20100004194USE OF ISOMALTULOSE IN FOOD PRODUCTS HAVING A REGENERATIVE EFFECT - The invention relates to the use of isomaltulose or mixtures of isomaltulose for the production of functional food products for improving the regeneration of individuals exposed to physical exertion.01-07-2010
20090247484Compounds - The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.10-01-2009
20090069269ORAL COMPOSITION CONTAINING DIFRUCTOSE ANHYDRIDE - An oral composition for increasing equol production by inner-intestinal bacteria, wherein such composition contains difructose anhydride as an active ingredient to activate the equol production function of inner-intestinal bacteria.03-12-2009
20110230437ORGANIC COMPOUNDS - A composition comprising a compound of formula I CH09-22-2011
20090209484PREVENTIVE AND/OR THERAPEUTIC AGENT FOR CALCIPENIA - The invention is to develop an agent having at least one of anricalclpenic, antiedemic and diuretic activities for humans or animals and to inhibit the postpartum drop of the calcium concentration in blood, thereby maintaining the health of the mother body and smoothing nursing and lactation.08-20-2009
20100152131METHOD FOR PRODUCING PURIFIED HEMATINIC IRON-SACCHARADIC COMPLEX AND PRODUCT PRODUCED - A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.06-17-2010
20100160251IMIDAZO COMPOUNDS - The present invention relates to the use of at least one lactose-derived C-glycoside of general formula (I):06-24-2010
20090048207HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF - The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.02-19-2009
20090048206Edible powder meterial having excellent shelf stability - The present invention provides a powder material obtained by drying an aqueous emulsion containing at least one component selected from the group consisting of perfumes, coloring agents and functional substances, trehalose and water-soluble hemicellulose. This powder material has excellent shelf stability of the perfume, coloring agent and/or functional substance, and can impart a desired fragrance, flavor, color and/or function stably to various drinks, foods, cosmetics and the like for a long period of time.02-19-2009
20130123209METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.05-16-2013
20080214493Use of Flavone Compounds as Potassium Channel Inhibitors - This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (I09-04-2008
20100227835SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA - Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.09-09-2010
20100216738Acaricidal Active Substance Combinations - The present invention relates to the use of active substance combinations which consist firstly of a known dihydrofuranone derivative and secondly of further known pesticidal active substances, which active substance combinations are used for controlling animal pests, in particular from the order of the mites.08-26-2010
20090318381Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment - The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.12-24-2009
20120245119METHOD FOR SEPARATING SIALYLLACTOSE MATERIAL - A method for easily and efficiently separating a sialyllactose material from a milk material is disclosed. The method comprises removing proteins from the milk material to obtain a protein-free liquid, adjusting the pH of the protein-free liquid to obtain a pH-adjusted liquid, and concentrating the pH-adjusted liquid by an ultrafiltration (UF) membrane. Since the method also allows separation of sialyllactose from lactose and minerals, sialyllactose can be obtained with high purity, making the sialyllactose material highly useful for food, pharmaceutical, and other applications.09-27-2012
20100298259PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME - The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one hyaluronic acid oligomer chosen from compounds containing from 1 to 6 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.11-25-2010
20100323983PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF, AND USES THEREOF - The invention relates to the combination of hyaluronic acid and of at least one hyaluronic acid oligomer constituted of 1 to 2 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.12-23-2010
20110245196NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES - The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.10-06-2011
20110124593Methods for determining chemotherapeutic agents targeting alpha-glucan pathways and uses thereof - The present invention provides methods for determining a putative antibacterial, the methods comprising determining whether the putative antibacterial inhibits GlgE or Rv3032. The present invention also provides the antibacterial, the pharmaceutical composition and the method of making the antibacterial as well as a method of treating a subject infected with a bacterial comprising administration of the antibacterial.05-26-2011
20120245120ZINC SUCROSE OCTASULFATES, THEIR PREPARATION, AND PHARMACEUTICAL AND COSMETIC USES THEREOF - The present invention relates to a zinc sucrose octasulfate of the general formula I, a process for preparing same and its use in the pharmaceutical and/or cosmetic field09-27-2012
20090215718CARBOHYDRATE COMPOSITION FOR FLAT GLUCOSE RESPONSE - A low-glycemic available carbohydrate composition of the invention contains the following components: 08-27-2009
20090215717Sulfated oligosaccharides - The invention relates to sulfated oligosaccharides, more particularly to new pharmaceutical uses of sulfated oligosaccharides. The invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic’, inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. The invention further provides use of a sulfated oligosaccharide in the preparation of a medicament for the treatment of acute and chronic inflammatory disorders of the airways of mammals. The invention yet further provides use of a sulfated oligosaccharide to preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.08-27-2009
20110082102USE OF PREBIOTIC GALACTO-OLIGOSACCHARIDES IN THE TREATMENT OF INTESTINAL INFLAMMATION - The present invention relates to the use of an oligosaccharide, in particular a non-digestible oligosaccharide, composition in the prevention or treatment of inflammation, in particular intestinal inflammation.04-07-2011
20110251153PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR HEMOGLOBINURIA OR MYOGLOBINURIA - A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided.10-13-2011
20120202767HYALURONIC ACID BASED MUCOADHESIVE THERAPEUTIC COMPOSITION FOR THE PREVENTION AND TREATMENT OF EPITHELIAL AND MUCOSAL LESIONS OF THE HUMAN BODY - A sucralfate and hyaluronic acid based mucoadhesive composition of very low viscosity and its physiologically acceptable salts for the treatment and prevention of epithelial and mucosal lesions of the human body.08-09-2012
20100279978METHODS OF REDUCING THE SEVERITY OF MUCOSITIS - The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.11-04-2010
20110009358AGENT FOR SUPPRESSING GLUCOSE LEVEL INCREASE, AGENT FOR SUPPRESSING BODY FAT ACCUMULATION AND FOOD COMPOUND - A method for reducing body fat accumulation is provided that includes: providing a reducer of body fat accumulation, wherein the reducer comprises isomaltulose; having an individual ingest the reducer; and having the individual consume a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides, wherein the reducer is ingested before or after or simultaneous with consuming the carbohydrate, and wherein the reducer reduces the individual's body fat accumulation caused by consuming the carbohydrate. The reducer of body fat accumulation includes isomaltulose (PALATINOSE™) as an active ingredient so that when the reducer is ingested and a carbohydrate having an α-1,6-glucosyl bond ratio of from 0% to less than 50% relative to the total bonds among constituent saccharides is consumed, accumulation of body fat resulting from ingesting the carbohydrate is reduced.01-13-2011
20110136757HYPERSULFATED DISACCHARIDE FORMULATIONS - Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds or types of compounds that improve the bioavailability of the disaccharides relative to delivery of the drug without such agents. The hypersulfated disaccharides are made from heparin or salts thereof.06-09-2011
20100168054Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation - The present invention relates to a novel process for the chemical synthesis of β-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine.07-01-2010
20120309708METHOD FOR TREATMENT OF LACTO-N-BIOSE-CONTAINING SOLUTION - The present invention relates to a method of treating a liquid composition containing lacto-N-biose, the method including: preparing a liquid composition containing lacto-N-biose having a pH at 25° C. of not less than 2.0 and not more than 5.5, and heating the liquid composition at a temperature of 65° C. or higher. The present invention can provide a treatment method that enables thermal decomposition of lacto-N-biose to be suppressed when a liquid composition containing lacto-N-biose is heated at a temperature of 65° C. or higher, a liquid preparation containing lacto-N-biose that is treated using the treatment method, a dried product produced from such a liquid preparation containing lacto-N-biose, and a method of producing a product containing lacto-N-biose.12-06-2012
20120309707SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES - The present invention relates to the use of a series of sulphated disaccharides for the preparation of a medicament for the treatment or prevention of a neurodegenerative and/or neurovascular disease, of a traumatic brain injury or of a traumatic spinal cord injury. The present invention also relates to the use of said sulphated disaccharides for the preparation of a neuroprotective medicament or of an antioxidant medicament. The neurodegenerative and/or neurovascular diseases are preferably: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke.12-06-2012
20110218171TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND - A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X′ each represents a phenyl, a naphthyl, R09-08-2011
20100075918HYALURONIDASE INHIBITORS AS ANTI-CANCER AGENTS - Specific inhibitors of hyaluronidase (HYA1-type hyaluronidase) are used to treat cancer, especially carcinoma and solid tumors, and/or precancerous conditions.03-25-2010
20090312281PROCESS FOR THE PREPARATION OF A PULVERULENT COMPOSITION AND PRODUCT AS OBTAINED - Method of preparing a non-hygroscopic pulverulent composition, includes a step for the spray drying, without an atomization support, of an aqueous solution containing at least one initially hygroscopic product, having a glass transition temperature ranging from 10° C. to 110° C., and a cryogenic fluid, especially a food-grade cryogenic fluid, or a mixture of cryogenic fluids, particularly chosen from liquid air, nitrogen and carbon dioxide, the aqueous solution being obtained by dissolving the cryogenic fluid in an initial aqueous solution containing the initially hygroscopic product.12-17-2009
20110071103METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.03-24-2011
20100190740OIL-IN-WATER EMULSION - The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and in that it contains at least one lipophilic surface-active agent with an HLB ranging from 2 to 5, at least one hydrophilic surface-active agent with an HLB ranging from 8 to 12 and at least one amphiphilic compound of ionic nature at a pH ranging from 3 to 5.5.07-29-2010
20110021455STERILISED SUCRALFATE GEL - The present invention relates to an autoclave-sterilized gel comprising sucralfate and at least 15% by weight of a humectant, relative to the total weight of gel, and having a pH of greater than or equal to 6, more particularly for use in a skin healing treatment by topical application.01-27-2011
20110028425Vesicle And Cosmetic Containing The Same - A vesicle according to the present invention is characterized in that it comprises a sucrose fatty acid diester and an acyl methyl taurate in an amount of 5 to 30 wt % relative to the diester and that the sucrose fatty acid diester is contained as a main component of membrane, and has excellent dispersion stability. Also the present invention includes a cosmetic comprising the vesicle and a lotion in which the vesicle is dispersed in a solvent containing alcohol.02-03-2011
20090005339Methods of Treating Ear Infections - Methods of treating and/or preventing otitis media in a subject are provided. Methods of treating and/or preventing otitis externa are also provided.01-01-2009
20120004192USE OF LACTULOSE IN THE TREATMENT OF AUTISM - A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.01-05-2012
20120004193PROCESS FOR PRODUCTION OF ORALLY INGESTIBLE COMPOSITION CONTAINING ARABINOFURANOSYL VITEXIN, AND USE OF THE COMPOSITION - A method for producing an orally ingestible composition containing an arabinofuranosyl vitexin and/or a hydrolysate thereof by using 01-05-2012
20110098244Process for Isolating Sialic Acid Containing Oligosaccharides, and the Compositions Containing Sialic Acid Containing Oligosaccharides Obtainable Thereby - The invention relates to a process for isolating sialic acid containing oligosaccharides and in particular sialyllactose from a milk stream and especially from a whey stream. The process yields a product having a high content of sialyllactose and a low content of phosphorus compounds. This product is highly suitable to be included in infant foods.04-28-2011
20090099127Nematicidal Compositions and Methods - A nematicidal composition includes (a) at least one carbamate and (b) at least one neonicotinoid and/or chloronicotinyle. In one exemplary embodiment, the carbamate can be an oxime carbamate, such as thiodicarb and the neonicotinoid can be a nitroguanidine. In one specific embodiment, the nitroguanidine includes imidacloprid and/or clothianidin. An exemplary method of the invention includes applying a composition of the invention to either soil or a plant (e.g., seeds or foliarly) to combat nematode damage and/or increase crop yield.04-16-2009
20090270342IMMUNOREGULATORY AGENT - An object of the present invention is to provide an immunoregulatory agent, which can be continuously ingested on daily diet and has no fear of causing side effects, and a method for regulating immunity. The present invention solves the above object by providing an immunoregulatory agent comprising lactosucrose as an effective ingredient and a method for regulating immunity using lactosucrose.10-29-2009
20120015901METHODS AND PREPARATIONS FOR PROTECTING CRITICALLY ILL PATIENTS - The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent.01-19-2012
20120022016Compounds and methods for selectively targeting tumor-associated mucins - The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.01-26-2012
20090137524SUBSTITUTED ARYLPYRAZOLES - This invention relates to a combination product comprising a compound of formula I05-28-2009
20120208782Modulation of Growth of Bifidobacteria Using a Combination of Oligosaccharides Found in Human Milk - A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of 08-16-2012
20100022469ANTHELMINTHIC FORMULATIONS - The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as livestock.01-28-2010
20120071436METHOD, COMPOSITION AND KIT FOR ANTIGENIC BINDING OF NORWALK-LIKE VIRUSES - A method for preventing or treating an active Norwalk-Like Virus (NLV) infection in the gastrointestinal (GI) tract of a host, comprising the step of administering orally a fucosyl α1→2 carbohydrate compound to the host, the compound having a binding specificity of the antigenic determinant of a human histo-blood group antigen and competitively binds with a NLV at the determinant binding site of the NLV. The compound inhibits binding of the NLV in vivo to a histo-blood group antigen of the host, thereby inhibiting the active infection or preventing infection of the GI tract of the host by the NLV.03-22-2012
20120252754Candy Cakes - Hyperkalemic Periodic Paralysis is a disease in mainly stock type horses that can be treated by giving the horse light corn syrup. Currently, the easiest way to do this is with a syringe, which is actually very difficult. The invention is a treat that will deliver a specific amount of light corn syrup per treat. This makes the entire process of delivering the corn syrup easier, faster, cleaner, and actually enjoyable for the horse. The treat can be used as an abortive measure, and also as a preventative measure if the owner incorporates the treat into the horses' daily routine. In addition to being used as the treatment for the disease, it can also be used as a regular treat for HYPP positive horses.10-04-2012
20120157406METHOD OF PREVENTING DIARRHOEA - The present invention provides a method for the prevention of the incidence of and/or a reduction in the duration of acute diarrhoea, particularly in travellers, said method comprising orally administering an oligosaccharide composition, in particular a non-digestible oligosaccharide, to a mammal.06-21-2012
20110105426COMPOSITIONS AND METHODS FOR TREATING CORNEAL INFLAMMATION - A method of treating corneal inflammation in a subject includes administering to the subject a therapeutically effective amount of a TLR4 antagonist.05-05-2011
20100093657LOW GLYCEMIC MIXTURES - The present invention relates to a food compound comprising an emulsion containing triglyceride oils as well as a low-glycemic saccharose isomer.04-15-2010
20120129802PROCESS FOR THE PRODUCTION OF ULTRAPURE GALACTO-OLIGOSACCHARIDES - The present invention describes a process for preparing ultrapure (≧95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving 05-24-2012
20120135955External Preparation Containing NSAIDs And Method For Producing The External Preparation - Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.05-31-2012
20100267658Trehalulose-containing composition, its preparation and use - The present invention relates to a trehalulose-containing composition, its preparation and use.10-21-2010
20120190643CARBOHYDRATE COMPOSITION FOR FLAT GLUCOSE RESPONSE - A low-glycemic available carbohydrate composition of the invention contains the following components: 07-26-2012
20100204174NOVEL ACTIVE INGREDIENT IN CICATRIZATION AND USE THEREOF - The present invention relates to the use of a known compound as an agent for promoting and/or accelerating fibroblast proliferation and/or differentiation and, consequently, cicatrization. This compound is a copolymer of a 2-methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulphonic acid salt and of propenoic acid 2-hydroxyethyl ester. It may be used alone or in combination with other active substances for inducing or accelerating cicatrization. This compound, alone or in combination with another active substance, may be administered directly on the wound and the surrounding area or the mucous membranes, by topical application. It may also be used ex vivo, in particular for generating cells for skin grafts.08-12-2010
20100204173METHODS OF TREATING HEPATIC ENCEPHALOPATHY - The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.08-12-2010
20120270832KETONE ACCUMULATION INHIBITOR - A ketone body accumulation inhibitor that inhibits the accumulation of ketone bodies caused by exercising is provided in the present invention. The ketone body accumulation inhibitor contains isomaltulose as an active ingredient.10-25-2012
20100234317USE OF DIFRUCTOSE ANHYDRIDE-CONTAINING COMPOSITION - A method for improving bowel movement of a subject desiring such an improvement, includes administering to the subject a defructose anhydride (DFA) in an amount effective to improve bowel movement.09-16-2010
20120277181LACTULOSE FOR BOWEL EVACUATION - A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed.11-01-2012
20120329750METHOD FOR PRODUCING PURIFIED HEMATINIC IRON-SACCHARIDIC COMPLEX AND PRODUCT PRODUCED - A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.12-27-2012
20110306574INHIBITORS OF F18+ E COLI BINDING - The present invention relates to blood group A/B/H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic 12-15-2011
20100168055COMBINATION OF MONOSACCHARIDE WITH C-GLYCOSIDE DERIVATIVE AND USE THEREOF - Composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, at least one of mannose, and rhamnose and at least one additional compound chosen from C-glycosides and C-glycoside derivatives. Use of such a composition, and also a device containing it.07-01-2010
20130018014New class of therapeutics that enhance small molecule diffusion - The subject application relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders.01-17-2013
200901182251-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury - The present invention is directed to nicotinamide derivatives, and their use in treating gastrointestinal disorders.05-07-2009
20110245197HYPERSULFATED GLUCOPYRANOSIDES - Hypersulfated disaccharides, preferably octasulfated sucrose, with utility in asthma or asthma related disorders are disclosed. The compounds may optionally be formulated with pharmaceutically acceptable excipients or delivery agents. The delivery agents are selected from the group consisting of natural or synthetic polymers, aerosols or other vehicles that facilitate the delivery or administration of the drug. The hypersulfated disaccharides are made from carbohydrate starting materials. Ion exchange or other suitable synthetic processes may be utilized to prepare the pharmaceuticals. The hypersulfated disaccharides are useful as anti-inflammatory agents.10-06-2011
20110275592EMULSION COMPOSITION AND FOOD AND COSMETIC PRODUCTS CONTAINING THE EMULSION COMPOSITION - The invention provides an emulsion composition obtained by mixing an oil phase containing a carotenoid having a melting point of 100° C. or more as detected when it is contained in an oil; and an aqueous phase containing a polyglycerol fatty acid ester and a nonionic emulsifier different from the polyglycerol fatty acid ester, wherein a weight ratio (A)/(B) of an amount (A) of the polyglycerol fatty acid ester to an amount (B) of the nonionic emulsifier different from the polyglycerol fatty acid ester is in the range of 2.5 to 10, and a particle diameter of dispersed particles that contain the carotenoid is 200 nm or less.11-10-2011
20110237538TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES - Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase.09-29-2011
20090197828SYSTEM, METHOD AND PACKAGE FOR PROVIDING A SUCROSE SOLUTION - A solution of sucrose and water is packaged and placed in an aseptic state in a cup-shaped container with a removable cover for single patient use. A plurality of containers is shipped from a preparation site to a site of usage such as a hospital. A single container of the solution is opened at a site of a procedure for a neonatal infant, and the solution administered prior to the procedure as well as during or afterward, as needed for analgesic effect. Any residual solution is discarded after the procedure to prevent cross contamination of other patients.08-06-2009
20110312910PHARMACEUTICAL COMPOSITION BASED ON A HEPATOPROTECTOR AND A PREBIOTIC, AND PRODUCTION AND APPLICATION THEREOF - The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses. The invention contributes to the liver's functional recovery in a short time and prevents disease recidivation owing to the recovery of cholesterol exchange and intestinal biocenosis as a result of the synergistic interaction of a hepatoprotector and a prebiotic, thereby also preventing hepatoprotector side effects.12-22-2011
20130190266FRUCTOSYLATED PUERARIN, AND PREPARATION METHOD AND USE THEREOF - Fructosylated puerarin being converted from puerarin by a bioconversion method conducted in an aqueous phase or nonaqueous phase system, including monofructosyl-(2,6)-puerarin, bifructosyl-(2,6)-puerarin, trifructosyl-(2,6)-puerarin, tetrafructosyl-(2,6)-puerarin and pentafructosyl-(2,6)-puerarin. Tests have shown that the oligosaccharylated puerarin is effective to treat acute myocardial ischemia, and can markedly suppress in vitro the proliferation of human breast cancer cell strain MDA-MB-23 and human chronmyelogenors leukemia cell strain K562, and it has a low toxicity.07-25-2013
20130196942Composition for Skin Treatment - A composition comprising from 10 to 15% by weight of sucrose palmitate. The composition can be used to treat eczema.08-01-2013
20130203695HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS - Hypersulfated disaccharides of formula I and other hypersulfated disaccharides disclosed herein are used to treat diseases or conditions associated with human neutrophil elastase imbalances. The disaccharides and/or intermediates useful to prepare such compounds are prepared from heparin. The diseases and conditions which are treated with a compound of formula I include chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF). The formulations are delivered to the lungs in an aerosol formulation or dry powder means or via nebulization. Oral forms are also suitable.08-08-2013
20130210759Composition for Use in the Treatment of Acne - A composition comprising from 10 to 15% by weight of sucrose palmitate which may be used in the treatment of acne.08-15-2013

Patent applications in class Dissacharide